Dare Bioscience Inc (DARE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dare Bioscience Inc (DARE) has a cash flow conversion efficiency ratio of 0.508x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.44 Million) by net assets ($2.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Dare Bioscience Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Dare Bioscience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read DARE total debt and obligations for a breakdown of total debt and financial obligations.
Dare Bioscience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dare Bioscience Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Korea Bio-Gen Co.Ltd
KQ:318000
|
0.040x |
|
Lithium Energy Ltd
AU:LEL
|
-0.041x |
|
Carmit
TA:CRMT
|
0.031x |
|
GTN Ltd
AU:GTN
|
0.077x |
|
Minerva Neurosciences Inc
NASDAQ:NERV
|
0.084x |
|
Gurktaler AG ST
VI:GAGS
|
-0.006x |
|
Daesung Eltec Co. Ltd
KQ:025440
|
0.061x |
|
India Globalization Capital Inc
NYSE MKT:IGC
|
-0.258x |
Annual Cash Flow Conversion Efficiency for Dare Bioscience Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Dare Bioscience Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Dare Bioscience Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.84 Million | $-9.89 Billion | -3477.715x | -387504.24% |
| 2024-12-31 | $-6.01 Million | $5.39 Million | -0.897x | -111.66% |
| 2023-12-31 | $-5.05 Million | $-38.86 Million | 7.698x | +572.90% |
| 2022-12-31 | $11.11 Million | $-18.09 Million | -1.628x | -119.32% |
| 2021-12-31 | $38.75 Million | $-28.76 Million | -0.742x | -103.39% |
| 2020-12-31 | $-1.15 Million | $-25.23 Million | 21.910x | +172.54% |
| 2019-12-31 | $440.83K | $-13.32 Million | -30.206x | -1878.71% |
| 2018-12-31 | $6.73 Million | $-10.27 Million | -1.527x | -698.85% |
| 2017-12-31 | $13.29 Million | $-2.54 Million | -0.191x | +92.53% |
| 2016-12-31 | $13.11 Million | $-33.54 Million | -2.558x | -290.65% |
| 2015-12-31 | $48.74 Million | $-31.91 Million | -0.655x | -55.70% |
| 2014-12-31 | $45.33 Million | $-19.06 Million | -0.421x | -107.06% |
| 2013-12-31 | $-2.79 Million | $-16.61 Million | 5.959x | +2170.70% |
| 2012-12-31 | $-80.04 Million | $-21.00 Million | 0.262x | +119.21% |
| 2011-12-31 | $12.35 Million | $-16.88 Million | -1.366x | -- |
About Dare Bioscience Inc
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of… Read more